Recovery of function following central nervous system damage requires the regeneration and rewiring of neurons. The major factors limiting regrowth are extracellular inhibitors in CNS tissue called Nogo-A, MAG and OMgp. The company has developed a decoy receptor – called Nogo Trap - that binds the growth inhibitors allowing the body to grow nerve fibers naturally and directly targeting restoration across all facets of growth: axonal regeneration (long distance), axonal sprouting (medium distance) and synaptic plasticity.
The Nogo Trap technology has been validated in a number of independent academic and pharmaceutical industry laboratories to show significant regrowth and recovery of function. The first indication addressed will be Chronic Spinal Cord Injury (SCI) followed by Acute SCI and glaucoma.
Manufacturing/Regulatory - The company has completed GMP manufacturing and toxicology testing and has received U.S. FDA authorization to proceed with a Phase 1/2 trial in patients with chronic spinal cord injury.
Patents - The company has licensed patents from Yale University and industry partners with protection for composition of matter as well as methods of use.
Interviews with Dr. Stephen Strittmatter, professor of neurology and neuroscience at the Yale School of Medicine and founder of ReNetX Bio
The Nogo Trap technology has been validated in a number of independent academic and pharmaceutical industry laboratories to show significant regrowth and recovery of function. The first indication addressed will be Chronic Spinal Cord Injury (SCI) followed by Acute SCI and glaucoma.
Manufacturing/Regulatory - The company has completed GMP manufacturing and toxicology testing and has received U.S. FDA authorization to proceed with a Phase 1/2 trial in patients with chronic spinal cord injury.
Patents - The company has licensed patents from Yale University and industry partners with protection for composition of matter as well as methods of use.
Interviews with Dr. Stephen Strittmatter, professor of neurology and neuroscience at the Yale School of Medicine and founder of ReNetX Bio
Podcast by Unite 2 Fight Paralysis, Jan 2020
A discussion about the preclinical research, the mechanistic activity, and the challenges of translating a discovery to clinical relevance
A discussion about the preclinical research, the mechanistic activity, and the challenges of translating a discovery to clinical relevance
Wings for Life Magazine Interview (published Dec 11, 2019)
The Wings for Life foundation has pledged $7M to support ReNetX Bio, founded on Dr. Strittmatter's work
The Wings for Life foundation has pledged $7M to support ReNetX Bio, founded on Dr. Strittmatter's work
Aug 4, 2017 (Video by Ed Stannard--New Haven Register)
Dr. Stephen Strittmatter talks about a new therapy to repair severed nerves in the central nervous system
Dr. Stephen Strittmatter talks about a new therapy to repair severed nerves in the central nervous system